VOR BIOPHARMA INC (VOR)
Health Care · Clinical-stage biopharmaceutical (cell and gene therapy) · NASDAQ
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
What VOR BIOPHARMA INC does
Vor Biopharma Inc. is a biopharmaceutical company focused on developing novel product candidates for blood disorders and cancers. The company is in the clinical development stage, advancing product candidates through clinical trials with the goal of obtaining regulatory approvals and commercializing these therapies. The company relies on strategic collaborations, internal research and development capabilities, and intellectual property licensed from third parties to advance its pipeline.
Themes: ["cell therapy","gene therapy","blood disorders","oncology","hematologic malignancies","clinical-stage development"]
Fundamentals
- Price$19.75 as of 2026-07-09 close
- Market cap$926M as of 2026-07-10
- 1-year return-57.7% as of 2026-07-09 close
- ROE-142.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.60 as of 2026-07-10
Key risks (from latest filing)
["Dependence on ability to successfully advance product candidates through clinical trials and obtain regulatory approval; clinical development involves substantial risks and uncertainties","Significant capital requirements to fund ongoing research, development, and potential commercialization efforts; need for additional funding with uncertain availability","Reliance on intellectual property licensed from third parties and ability to maintain such licenses on commercially reasonable terms"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.